Showcases Stock ranks

Mallinckrodt plc (MNK) (MNK)
2.23 -0.09 (-3.88%) 03-27 16:02
Open: 2.21 Pre. Close: 2.32
High: 2.255 Low: 2.07
Volume: 2,182,296 Market Cap: 188M
Mallinckrodt PLC is a drug manufacturing company that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products. It operates in two segments including branded pharmaceuticals and generic drugs.
Share on Facebook   Tweet this page
Price Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 2.262 - 2.273 2.273 - 2.281
Low: 2.044 - 2.059 2.059 - 2.068
Close: 2.208 - 2.231 2.231 - 2.246
Stock Technical Analysis
Target: Six months: 4.91
One year: 7.23
Support: Support1:
Support2: 0.83
Resistance: Resistance1: 4.21
Resistance2: 6.19
Pivot: 2.12
Moving Averages: MA(5): 2.09
MA(20): 2.41
MA(100): 3.66
MA(250): 6.58
MACD: MACD(12,26): -0.55
Signal(12,26,9): -0.63
%K %D: %K(14,3): 41.87
%D(3): 37.57
RSI: RSI(14): 43.53
52-Week: High: 23.9
Low: 1
Change(%): -90.0
Average Vol(K): 3-Month: 894242
10-Days: 884333
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

MNK has closed below upper band by 45.7%. Bollinger Bands are 42.6% wider than normal. The large width of the bands suggest high volatility as compared to MNK's normal range. The bands have been in this wide range for 18 bars. This is a sign that the current trend might continue.
Stock chart
Stock News
Mallinckrodt Completes NDA Submission for Kidney Failure Drug
Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.

Mallinckrodt faces 'existential threat' after losing Medicaid drug rebate case
Drugmaker Mallinckrodt Plc on Monday warned that a judge's ruling allowing the federal government to force it to pay higher rebates to state Medicaid programs after raising its top-selling drug's price posed an "existential threat to the company."

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty Generic
Shares Out. (M) 84.09
Shares Float (M) 77.68
% Held by Insiders 2.78
% Held by Institutions 97.03
Shares Short (K) 48480
Shares Short Prior Month (K) 44000
Stock Financials
EPS -11.877
Book Value (p.s.) 23.080
PEG Ratio
Profit Margin -31.51
Operating Margin 8.02
Return on Assets (ttm) 1.5
Return on Equity (ttm) -41.7
Qtrly Rev. Growth -3.6
Gross Profit (p.s.) 17.006
Sales Per Share 37.579
EBITDA (p.s.) 14.270
Qtrly Earnings Growth
Operating Cash Flow (M) 742.90
Levered Free Cash Flow (M) 708.70
Stock Valuation
P/E -0.19
P/E Growth Ratio -0.04
P/BV 0.10
P/CF 0.25
Dividend Yield
Dividends & Splits
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2012-12-11
Last Split Ratio 0.5

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator